Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

BORIS Expression in Ovarian Cancer Precursor Cells Alters the CTCF Cistrome and Enhances Invasiveness through GALNT14.

Hillman JC, Pugacheva EM, Barger CJ, Sribenja S, Rosario S, Albahrani M, Truskinovsky AM, Stablewski A, Liu S, Loukinov DI, Zentner GE, Lobanenkov VV, Karpf AR, Higgins MJ.

Mol Cancer Res. 2019 Oct;17(10):2051-2062. doi: 10.1158/1541-7786.MCR-19-0310. Epub 2019 Jul 10.

PMID:
31292201
2.

CTCF Expression is Essential for Somatic Cell Viability and Protection Against Cancer.

Bailey CG, Metierre C, Feng Y, Baidya K, Filippova GN, Loukinov DI, Lobanenkov VV, Semaan C, Rasko JE.

Int J Mol Sci. 2018 Nov 30;19(12). pii: E3832. doi: 10.3390/ijms19123832.

3.

Targeting CTCFL/BORIS for the immunotherapy of cancer.

Loukinov D.

Cancer Immunol Immunother. 2018 Dec;67(12):1955-1965. doi: 10.1007/s00262-018-2251-8. Epub 2018 Nov 2. Review.

PMID:
30390146
4.

The downregulation of putative anticancer target BORIS/CTCFL in an addicted myeloid cancer cell line modulates the expression of multiple protein coding and ncRNA genes.

Teplyakov E, Wu Q, Liu J, Pugacheva EM, Loukinov D, Boukaba A, Lobanenkov V, Strunnikov A.

Oncotarget. 2017 Sep 2;8(43):73448-73468. doi: 10.18632/oncotarget.20627. eCollection 2017 Sep 26.

5.

The cancer-associated CTCFL/BORIS protein targets multiple classes of genomic repeats, with a distinct binding and functional preference for humanoid-specific SVA transposable elements.

Pugacheva EM, Teplyakov E, Wu Q, Li J, Chen C, Meng C, Liu J, Robinson S, Loukinov D, Boukaba A, Hutchins AP, Lobanenkov V, Strunnikov A.

Epigenetics Chromatin. 2016 Aug 31;9(1):35. doi: 10.1186/s13072-016-0084-2. eCollection 2016.

6.

Comparative analyses of CTCF and BORIS occupancies uncover two distinct classes of CTCF binding genomic regions.

Pugacheva EM, Rivero-Hinojosa S, Espinoza CA, Méndez-Catalá CF, Kang S, Suzuki T, Kosaka-Suzuki N, Robinson S, Nagarajan V, Ye Z, Boukaba A, Rasko JE, Strunnikov AV, Loukinov D, Ren B, Lobanenkov VV.

Genome Biol. 2015 Aug 14;16:161. doi: 10.1186/s13059-015-0736-8.

7.

Differential regulation of MAGE-A1 promoter activity by BORIS and Sp1, both interacting with the TATA binding protein.

Schwarzenbach H, Eichelser C, Steinbach B, Tadewaldt J, Pantel K, Lobanenkov V, Loukinov D.

BMC Cancer. 2014 Nov 3;14:796. doi: 10.1186/1471-2407-14-796.

8.

Loss of maternal CTCF is associated with peri-implantation lethality of Ctcf null embryos.

Moore JM, Rabaia NA, Smith LE, Fagerlie S, Gurley K, Loukinov D, Disteche CM, Collins SJ, Kemp CJ, Lobanenkov VV, Filippova GN.

PLoS One. 2012;7(4):e34915. doi: 10.1371/journal.pone.0034915. Epub 2012 Apr 20.

9.

Condensin dysfunction in human cells induces nonrandom chromosomal breaks in anaphase, with distinct patterns for both unique and repeated genomic regions.

Samoshkin A, Dulev S, Loukinov D, Rosenfeld JA, Strunnikov AV.

Chromosoma. 2012 Apr;121(2):191-9. doi: 10.1007/s00412-011-0353-6. Epub 2011 Dec 17.

PMID:
22179743
11.

Transcription factor BORIS (Brother of the Regulator of Imprinted Sites) directly induces expression of a cancer-testis antigen, TSP50, through regulated binding of BORIS to the promoter.

Kosaka-Suzuki N, Suzuki T, Pugacheva EM, Vostrov AA, Morse HC 3rd, Loukinov D, Lobanenkov V.

J Biol Chem. 2011 Aug 5;286(31):27378-88. doi: 10.1074/jbc.M111.243576. Epub 2011 Jun 9.

12.

Cancer-testis antigen, BORIS based vaccine delivered by dendritic cells is extremely effective against a very aggressive and highly metastatic mouse mammary carcinoma.

Mkrtichyan M, Ghochikyan A, Davtyan H, Movsesyan N, Loukinov D, Lobanenkov V, Cribbs DH, Laust AK, Nelson EL, Agadjanyan MG.

Cell Immunol. 2011;270(2):188-97. doi: 10.1016/j.cellimm.2011.05.007. Epub 2011 May 12.

13.

The structural complexity of the human BORIS gene in gametogenesis and cancer.

Pugacheva EM, Suzuki T, Pack SD, Kosaka-Suzuki N, Yoon J, Vostrov AA, Barsov E, Strunnikov AV, Morse HC 3rd, Loukinov D, Lobanenkov V.

PLoS One. 2010 Nov 8;5(11):e13872. doi: 10.1371/journal.pone.0013872.

14.

BORIS/CTCFL-mediated transcriptional regulation of the hTERT telomerase gene in testicular and ovarian tumor cells.

Renaud S, Loukinov D, Alberti L, Vostrov A, Kwon YW, Bosman FT, Lobanenkov V, Benhattar J.

Nucleic Acids Res. 2011 Feb;39(3):862-73. doi: 10.1093/nar/gkq827. Epub 2010 Sep 28.

15.

Expression of a testis-specific form of Gal3st1 (CST), a gene essential for spermatogenesis, is regulated by the CTCF paralogous gene BORIS.

Suzuki T, Kosaka-Suzuki N, Pack S, Shin DM, Yoon J, Abdullaev Z, Pugacheva E, Morse HC 3rd, Loukinov D, Lobanenkov V.

Mol Cell Biol. 2010 May;30(10):2473-84. doi: 10.1128/MCB.01093-09. Epub 2010 Mar 15.

16.

Epigenetic regulation of caspase-3 gene expression in rat brain development.

Yakovlev A, Khafizova M, Abdullaev Z, Loukinov D, Kondratyev A.

Gene. 2010 Jan 15;450(1-2):103-8. doi: 10.1016/j.gene.2009.10.008.

17.

PAX5 activates the transcription of the human telomerase reverse transcriptase gene in B cells.

Bougel S, Renaud S, Braunschweig R, Loukinov D, Morse HC 3rd, Bosman FT, Lobanenkov V, Benhattar J.

J Pathol. 2010 Jan;220(1):87-96. doi: 10.1002/path.2620.

18.

Genome wide ChIP-chip analyses reveal important roles for CTCF in Drosophila genome organization.

Smith ST, Wickramasinghe P, Olson A, Loukinov D, Lin L, Deng J, Xiong Y, Rux J, Sachidanandam R, Sun H, Lobanenkov V, Zhou J.

Dev Biol. 2009 Apr 15;328(2):518-28. doi: 10.1016/j.ydbio.2008.12.039. Epub 2009 Jan 8.

19.

Human gamma-satellite DNA maintains open chromatin structure and protects a transgene from epigenetic silencing.

Kim JH, Ebersole T, Kouprina N, Noskov VN, Ohzeki J, Masumoto H, Mravinac B, Sullivan BA, Pavlicek A, Dovat S, Pack SD, Kwon YW, Flanagan PT, Loukinov D, Lobanenkov V, Larionov V.

Genome Res. 2009 Apr;19(4):533-44. doi: 10.1101/gr.086496.108. Epub 2009 Jan 13.

20.

DNA, but not protein vaccine based on mutated BORIS antigen significantly inhibits tumor growth and prolongs the survival of mice.

Mkrtichyan M, Ghochikyan A, Loukinov D, Davtyan H, Ichim TE, Cribbs DH, Lobanenkov VV, Agadjanyan MG.

Gene Ther. 2008 Jan;15(1):61-4. Epub 2007 Nov 1.

21.

Expression of the CTCF-paralogous cancer-testis gene, brother of the regulator of imprinted sites (BORIS), is regulated by three alternative promoters modulated by CpG methylation and by CTCF and p53 transcription factors.

Renaud S, Pugacheva EM, Delgado MD, Braunschweig R, Abdullaev Z, Loukinov D, Benhattar J, Lobanenkov V.

Nucleic Acids Res. 2007;35(21):7372-88. Epub 2007 Oct 25.

22.

Evolutionary diversification of SPANX-N sperm protein gene structure and expression.

Kouprina N, Noskov VN, Pavlicek A, Collins NK, Schoppee Bortz PD, Ottolenghi C, Loukinov D, Goldsmith P, Risinger JI, Kim JH, Westbrook VA, Solomon G, Sounders H, Herr JC, Jurka J, Lobanenkov V, Schlessinger D, Larionov V.

PLoS One. 2007 Apr 4;2(4):e359.

23.

Analysis of the vertebrate insulator protein CTCF-binding sites in the human genome.

Kim TH, Abdullaev ZK, Smith AD, Ching KA, Loukinov DI, Green RD, Zhang MQ, Lobanenkov VV, Ren B.

Cell. 2007 Mar 23;128(6):1231-45.

24.

Global expression analysis of cancer/testis genes in uterine cancers reveals a high incidence of BORIS expression.

Risinger JI, Chandramouli GV, Maxwell GL, Custer M, Pack S, Loukinov D, Aprelikova O, Litzi T, Schrump DS, Murphy SK, Berchuck A, Lobanenkov V, Barrett JC.

Clin Cancer Res. 2007 Mar 15;13(6):1713-9.

25.

Dual role of DNA methylation inside and outside of CTCF-binding regions in the transcriptional regulation of the telomerase hTERT gene.

Renaud S, Loukinov D, Abdullaev Z, Guilleret I, Bosman FT, Lobanenkov V, Benhattar J.

Nucleic Acids Res. 2007;35(4):1245-56. Epub 2007 Jan 31.

26.

A CTCF-binding silencer regulates the imprinted genes AWT1 and WT1-AS and exhibits sequential epigenetic defects during Wilms' tumourigenesis.

Hancock AL, Brown KW, Moorwood K, Moon H, Holmgren C, Mardikar SH, Dallosso AR, Klenova E, Loukinov D, Ohlsson R, Lobanenkov VV, Malik K.

Hum Mol Genet. 2007 Feb 1;16(3):343-54. Epub 2007 Jan 8.

PMID:
17210670
27.

CTCF interacts with and recruits the largest subunit of RNA polymerase II to CTCF target sites genome-wide.

Chernukhin I, Shamsuddin S, Kang SY, Bergström R, Kwon YW, Yu W, Whitehead J, Mukhopadhyay R, Docquier F, Farrar D, Morrison I, Vigneron M, Wu SY, Chiang CM, Loukinov D, Lobanenkov V, Ohlsson R, Klenova E.

Mol Cell Biol. 2007 Mar;27(5):1631-48. Epub 2007 Jan 8.

28.

Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites.

Ghochikyan A, Mkrtichyan M, Loukinov D, Mamikonyan G, Pack SD, Movsesyan N, Ichim TE, Cribbs DH, Lobanenkov VV, Agadjanyan MG.

J Immunol. 2007 Jan 1;178(1):566-73.

29.

Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant.

Loukinov D, Ghochikyan A, Mkrtichyan M, Ichim TE, Lobanenkov VV, Cribbs DH, Agadjanyan MG.

J Cell Biochem. 2006 Aug 1;98(5):1037-43.

PMID:
16741971
30.

Cloning and characterization of zebrafish CTCF: Developmental expression patterns, regulation of the promoter region, and evolutionary aspects of gene organization.

Pugacheva EM, Kwon YW, Hukriede NA, Pack S, Flanagan PT, Ahn JC, Park JA, Choi KS, Kim KW, Loukinov D, Dawid IB, Lobanenkov VV.

Gene. 2006 Jun 21;375:26-36. Epub 2006 May 2.

PMID:
16647825
31.

CTCF binds the proximal exonic region of hTERT and inhibits its transcription.

Renaud S, Loukinov D, Bosman FT, Lobanenkov V, Benhattar J.

Nucleic Acids Res. 2005 Dec 2;33(21):6850-60. Print 2005.

32.

Rasgrf1 imprinting is regulated by a CTCF-dependent methylation-sensitive enhancer blocker.

Yoon B, Herman H, Hu B, Park YJ, Lindroth A, Bell A, West AG, Chang Y, Stablewski A, Piel JC, Loukinov DI, Lobanenkov VV, Soloway PD.

Mol Cell Biol. 2005 Dec;25(24):11184-90.

33.

Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells.

Hong JA, Kang Y, Abdullaev Z, Flanagan PT, Pack SD, Fischette MR, Adnani MT, Loukinov DI, Vatolin S, Risinger JI, Custer M, Chen GA, Zhao M, Nguyen DM, Barrett JC, Lobanenkov VV, Schrump DS.

Cancer Res. 2005 Sep 1;65(17):7763-74.

34.

Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes.

Vatolin S, Abdullaev Z, Pack SD, Flanagan PT, Custer M, Loukinov DI, Pugacheva E, Hong JA, Morse H 3rd, Schrump DS, Risinger JI, Barrett JC, Lobanenkov VV.

Cancer Res. 2005 Sep 1;65(17):7751-62.

35.

Heightened expression of CTCF in breast cancer cells is associated with resistance to apoptosis.

Docquier F, Farrar D, D'Arcy V, Chernukhin I, Robinson AF, Loukinov D, Vatolin S, Pack S, Mackay A, Harris RA, Dorricott H, O'Hare MJ, Lobanenkov V, Klenova E.

Cancer Res. 2005 Jun 15;65(12):5112-22.

36.

Familial cases of point mutations in the XIST promoter reveal a correlation between CTCF binding and pre-emptive choices of X chromosome inactivation.

Pugacheva EM, Tiwari VK, Abdullaev Z, Vostrov AA, Flanagan PT, Quitschke WW, Loukinov DI, Ohlsson R, Lobanenkov VV.

Hum Mol Genet. 2005 Apr 1;14(7):953-65. Epub 2005 Feb 24.

PMID:
15731119
37.

Chromatin architecture near a potential 3' end of the igh locus involves modular regulation of histone modifications during B-Cell development and in vivo occupancy at CTCF sites.

Garrett FE, Emelyanov AV, Sepulveda MA, Flanagan P, Volpi S, Li F, Loukinov D, Eckhardt LA, Lobanenkov VV, Birshtein BK.

Mol Cell Biol. 2005 Feb;25(4):1511-25.

38.

CTCF is conserved from Drosophila to humans and confers enhancer blocking of the Fab-8 insulator.

Moon H, Filippova G, Loukinov D, Pugacheva E, Chen Q, Smith ST, Munhall A, Grewe B, Bartkuhn M, Arnold R, Burke LJ, Renkawitz-Pohl R, Ohlsson R, Zhou J, Renkawitz R, Lobanenkov V.

EMBO Rep. 2005 Feb;6(2):165-70.

39.

Transcriptional regulator CTCF controls human interleukin 1 receptor-associated kinase 2 promoter.

Kuzmin I, Geil L, Gibson L, Cavinato T, Loukinov D, Lobanenkov V, Lerman MI.

J Mol Biol. 2005 Feb 18;346(2):411-22. Epub 2004 Dec 22.

PMID:
15670593
40.

BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma.

Loukinov DI, Pugacheva E, Vatolin S, Pack SD, Moon H, Chernukhin I, Mannan P, Larsson E, Kanduri C, Vostrov AA, Cui H, Niemitz EL, Rasko JE, Docquier FM, Kistler M, Breen JJ, Zhuang Z, Quitschke WW, Renkawitz R, Klenova EM, Feinberg AP, Ohlsson R, Morse HC 3rd, Lobanenkov VV.

Proc Natl Acad Sci U S A. 2002 May 14;99(10):6806-11.

41.

Platelet-derived growth factor (PDGF)-induced tyrosine phosphorylation of the low density lipoprotein receptor-related protein (LRP). Evidence for integrated co-receptor function betwenn LRP and the PDGF.

Loukinova E, Ranganathan S, Kuznetsov S, Gorlatova N, Migliorini MM, Loukinov D, Ulery PG, Mikhailenko I, Lawrence DA, Strickland DK.

J Biol Chem. 2002 May 3;277(18):15499-506. Epub 2002 Feb 19.

42.

Tumor-associated zinc finger mutations in the CTCF transcription factor selectively alter tts DNA-binding specificity.

Filippova GN, Qi CF, Ulmer JE, Moore JM, Ward MD, Hu YJ, Loukinov DI, Pugacheva EM, Klenova EM, Grundy PE, Feinberg AP, Cleton-Jansen AM, Moerland EW, Cornelisse CJ, Suzuki H, Komiya A, Lindblom A, Dorion-Bonnet F, Neiman PE, Morse HC 3rd, Collins SJ, Lobanenkov VV.

Cancer Res. 2002 Jan 1;62(1):48-52.

43.

Cell growth inhibition by the multifunctional multivalent zinc-finger factor CTCF.

Rasko JE, Klenova EM, Leon J, Filippova GN, Loukinov DI, Vatolin S, Robinson AF, Hu YJ, Ulmer J, Ward MD, Pugacheva EM, Neiman PE, Morse HC 3rd, Collins SJ, Lobanenkov VV.

Cancer Res. 2001 Aug 15;61(16):6002-7.

44.
45.

Functional phosphorylation sites in the C-terminal region of the multivalent multifunctional transcriptional factor CTCF.

Klenova EM, Chernukhin IV, El-Kady A, Lee RE, Pugacheva EM, Loukinov DI, Goodwin GH, Delgado D, Filippova GN, León J, Morse HC 3rd, Neiman PE, Lobanenkov VV.

Mol Cell Biol. 2001 Mar;21(6):2221-34.

46.

Role of the beta-strand insert in the central domain of the fibrinogen gamma-module.

Yakovlev S, Litvinovich S, Loukinov D, Medved L.

Biochemistry. 2000 Dec 26;39(51):15721-9.

PMID:
11123897
47.

Functional association of CTCF with the insulator upstream of the H19 gene is parent of origin-specific and methylation-sensitive.

Kanduri C, Pant V, Loukinov D, Pugacheva E, Qi CF, Wolffe A, Ohlsson R, Lobanenkov VV.

Curr Biol. 2000 Jul 13;10(14):853-6.

48.

Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial.

Mincheff M, Tchakarov S, Zoubak S, Loukinov D, Botev C, Altankova I, Georgiev G, Petrov S, Meryman HT.

Eur Urol. 2000 Aug;38(2):208-17.

PMID:
10895014
49.

Functional domains of the very low density lipoprotein receptor: molecular analysis of ligand binding and acid-dependent ligand dissociation mechanisms.

Mikhailenko I, Considine W, Argraves KM, Loukinov D, Hyman BT, Strickland DK.

J Cell Sci. 1999 Oct;112 ( Pt 19):3269-81.

50.

Identification of a novel recognition sequence for integrin alphaM beta2 within the gamma-chain of fibrinogen.

Ugarova TP, Solovjov DA, Zhang L, Loukinov DI, Yee VC, Medved LV, Plow EF.

J Biol Chem. 1998 Aug 28;273(35):22519-27.

Supplemental Content

Loading ...
Support Center